Skip to main content

Table 1 Summary of patients with GIST

From: Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective

Patient Age, Gender Site Presentation Maximum diameter (mm) CD117 & CD34 Mitosis per HPF Operation Imatinib Follow up (months) Risk
1 66, F Stomach Mass 70 Positive 10/50 Wedge resection No 5, SD High
2 82, M stomach GI bleed 60 Positive 2/50 Wedge resection No 12, SD Inter
3 60, M Stomach GI bleed 75 Positive 2/50 Lap to open Wedge resection No 12, SD Inter
4 72, M Stomach Pain and distension 110 Positive 300/50 Debulking Yes 22, SD High
5 51, M Stomach Mass 14.5 Positive None seen Inoperable* Yes 3, PD High
6 61, F ?Stomach/?extra-gasttrointestinal Mass and distension 260 Positive 8/50 Excision and total hysterectomy Yes # 45, SD High
7 72, M Stomach Mass 90 Positive 17/50 Inoperable** Yes 6, Died of MI High
8 68, F Stomach GI bleed 70 Positive 4/50 Lap. wedge resection No 24, SD Inter
9 70, F Oesophagus Dysphagia 20 N/A N/A Not fit No 29, SD N/A
10 46, F Stomach GI bleed 70 Positive 10/50 Distal gastrectomy No 3 < SD High
11 77, F Stomach GI bleed 80 Positive 34/50 Distal gastrectomy No 9, Died High
12 47, M Stomach GI bleed 50 Not done Not done Wedge resection No 72, SD N/A
13 60, M Duodenum Incidental 13 N/A N/A Not fit No 14, SD N/A
14 74, F Stomach GI bleed 40 Positive 2/50 Lap. wedge resection No 9, SD Low
15 57, M Duodenum Cholangitis 40 Positive Negative None Duodenectomy No 62, SD Low
16 76, M Stomach GI bleed 65 Negative 2/50 No Yes 7, SD Inter
  1. N/A: No histological diagnosis available
  2. *: Metastatic disease
  3. **: locally advanced
  4. #: Imatinib was commenced 2 years after the operation when patient was found to have recurrence.
  5. SD: static disease at last follow up.
  6. PD: progressive disease at last follow up.